Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,830 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05997043RecruitingEarly Phase 1
Botulinum toxin for overactive bladder in Parkinson's disease
This trial tests if botulinum toxin A injections can help control overactive bladder symptoms in people with Parkinson's disease who haven't gotten enough relief from standard bladder medications. It aims to see if the treatment is safe and effective.
Guangzhou, GuangdongAges 25–80 - NCT05998694Recruiting
Monitoring a new aortic heart valve for safety and effectiveness
This trial tests how well a new replacement heart valve works and how safe it is. You might qualify if you need a planned first-time aortic valve replacement and are 60-70 years old (or younger if you cannot take blood thinners).
Kemerovo, Kemerovo OblastAges 60–70 - NCT05998928RecruitingPhase 2
BCMA-GPRC5D CAR-T for relapsed or refractory multiple myeloma
This trial tests a new cell therapy (CAR-T) that targets two proteins on myeloma cells for patients whose cancer has returned or not responded after at least three prior treatments. It aims to see if this therapy is safe and effective.
Wuhan, HubeiAges 18–75 - NCT06002789RecruitingPhase 2
PD-1 immunotherapy with or without chemo before surgery for colorectal cancer
This trial tests a medicine called PD-1 (a type of immunotherapy that helps your immune system fight cancer), sometimes with chemotherapy, before surgery for a certain type of colorectal cancer. It is for people whose tumors have a specific DNA repair problem (dMMR or MSI-H) and whose cancer has not spread to distant organs.
Guangzhou, GuangdongAges 18–80 - NCT06010329RecruitingPhase 2
Study of a new pill for advanced lung cancer with rare EGFR mutations
This trial tests an experimental pill called Sutetinib for people with advanced non-small cell lung cancer that has a rare EGFR gene change. It aims to see if the drug can shrink tumors and improve survival.
Glendale, CaliforniaAges 18 years+ - NCT06010342RecruitingPhase 2
TL118 for solid tumors with NTRK fusion
This trial tests an experimental pill called TL118 for people whose solid tumors have a specific NTRK gene fusion. It aims to see if the drug can shrink tumors or slow their growth when other treatments have stopped working or aren't an option.
Glendale, CaliforniaAges 18 years+ - NCT06011889RecruitingPhase 2/Phase 3
Etanercept for treating SAPHO syndrome
This study tests if etanercept, a biologic drug that targets inflammation, safely reduces pain and disease activity in people with SAPHO syndrome.
Warsaw, Masovian VoivodeshipAges 18 years+ - NCT06012552RecruitingPhase 2
Tianeptine for COVID-19 brain fog
This study tests whether the medication tianeptine can improve brain fog and thinking problems that persist after COVID-19. It may help if you are 18 or older, have had COVID-19, and have noticed new memory or concentration issues.
WarsawAges 18 years+ - NCT06013111RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced solid tumors
This trial tests a new treatment called Anti-CEA-CAR-T cells, which are specially modified immune cells that target a protein called CEA found on certain cancer cells. It is for people with advanced solid tumors, especially digestive system cancers, that have not responded to other treatments.
Shenyang, LiaoningAges 18–70 - NCT06017362RecruitingPhase 4
Insulin drops for dry eye in glaucoma patients
This study tests whether insulin eye drops can safely help dry eye in people who also use eye drops for glaucoma. It may offer a new option if you have both conditions and your eye pressure is stable.
Madrid, MadridAges 18 years+ - NCT06022003RecruitingPhase 2
Azacitidine plus gilteritinib for FLT3-mutated AML
This trial tests whether adding an oral chemotherapy pill (azacitidine) to the targeted drug gilteritinib helps people whose FLT3-mutated AML came back or didn't respond after their first treatment. The goal is to see if the combination is more effective than gilteritinib alone.
AmiensAges 18 years+ - NCT06022861RecruitingPhase 3
Study of LY01015 vs Opdivo with chemo for advanced esophageal cancer
This trial tests a new drug, LY01015, against Opdivo when both are given with chemotherapy for advanced or metastatic esophageal squamous cell carcinoma. It aims to see if LY01015 works as well as Opdivo and has similar safety.
GuangzhouAges 18–75 - NCT06041620Recruiting
Gene-edited stem cell therapy for beta-thalassemia
This trial tests a new treatment that uses your own blood stem cells, edited with CRISPR technology, to reduce or eliminate the need for blood transfusions in people with beta-thalassemia.
Tianjin, Tianjin MunicipalityAges 3–35 - NCT06045091RecruitingEarly Phase 1
BCMA-targeted CAR-NK cells for multiple myeloma or plasma cell leukemia
This trial tests an experimental therapy using immune cells (CAR-NK cells) designed to target and kill cancer cells in people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to treatment. The goal is to see if it is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06051513Recruiting
Testing colistimethate for CRE infection in hospitalized patients
This trial tests a medicine called colistimethate sodium for people in the hospital with a serious infection (pneumonia or bloodstream infection) caused by a resistant bacteria called CRE. The goal is to see if this antibiotic can effectively treat the infection.
Hefei, AnhuiAges 18–85 - NCT06052332Recruiting
Comparing two pre-surgery treatments for older adults with rectal cancer
This study compares two approaches to treating rectal cancer in people age 70 and older who have not yet had surgery. One approach gives chemotherapy and radiation before surgery, and the other adds more chemotherapy after radiation. The goal is to find which plan works better with fewer side effects.
Antwerp, AntwerpenAges 70 years+ - NCT06051695RecruitingPhase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06056115Recruiting
Tislelizumab for lung cancer with brain metastases
This trial tests a drug called tislelizumab for people with advanced lung adenocarcinoma that has spread to the brain but is not causing symptoms. It is for those who have not had prior treatment and whose tumors do not have certain gene changes.
Shijiazhuang, HebeiAges 18–75 - NCT06056921RecruitingPhase 1
CAR T-cell therapy for hard-to-treat autoimmune diseases
This trial tests a new treatment using your own immune cells (CAR T-cells) targeting a protein called CD19 to control severe autoimmune diseases like lupus, Sjogren's, scleroderma, dermatomyositis, or vasculitis. The goal is to see if it's safe and can improve symptoms when other treatments haven't worked.
Taiyuan, ShanxiAges 18 years+ - NCT06064864Recruiting
Switching Infliximab from IV to Subcutaneous for Crohn's
This study tests whether switching from an IV infliximab to a subcutaneous (under-the-skin) version is safe and works well for people with moderate to severe Crohn's disease. It's for people who have never used a biologic and need a new treatment option.
SeoulAges 18–100 - NCT06075433Recruiting
One year of blood thinners after a GENOSS stent for heart disease
This study tests whether taking two blood thinners for one year after getting a special GENOSS stent is safe and works well for people with coronary artery disease, especially if the stent placement was complex. The goal is to prevent blood clots and keep your artery open.
Wŏnju, Gangwon StateAges 19 years+ - NCT06079398RecruitingPhase 2
Weekly injection for infants with achondroplasia
This trial tests a new weekly injection called TransCon CNP for infants with achondroplasia (the most common form of dwarfism). The goal is to see if it can help children grow better than a placebo (a shot with no medicine).
Saint Paul, MinnesotaAges birth–2 years - NCT06080789RecruitingPhase 2
Study of a single injection of RABI-767 for severe acute pancreatitis
This trial tests a single injection of a new drug called RABI-767, given through a thin tube during an endoscopic ultrasound (EUS), to see if it can help people with severe acute pancreatitis. The drug is meant to reduce inflammation and prevent complications.
Little Rock, ArkansasAges 18–85 - NCT06081062RecruitingPhase 3
Testing Fabagal in people with Fabry disease
This trial is testing a new enzyme replacement therapy called Fabagal for people with Fabry disease who have not had prior treatment. It aims to see if it helps with kidney, heart, or brain problems caused by the disease.
ManilaAges 8 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,830 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.